和誉-B(02256.HK)：FGFR2/3抑制剂ABSK061治疗软骨发育不全临床试验完成首例患者给药

Core Viewpoint - The company announced the successful administration of the first patient in a Phase II clinical trial for its selective small molecule FGFR2/3 inhibitor, ABSK061, targeting children aged 3-12 with achondroplasia (ACH) [1] Group 1 - The subsidiary Shanghai Heyu Biopharmaceutical Technology Co., Ltd. is responsible for the development of ABSK061 [1] - The clinical trial focuses on a specific patient demographic, namely children with a rare genetic condition affecting bone growth [1]